Junshi Biotech: Application for marketing of treprilizumab as a new indication for first-line treatment of renal cell carcinoma was approved

新浪港股 · Apr 7 19:23

Junshi Biotech (01877) issued an announcement. The company received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and the marketing application for treprilimab (trade name: Tuoyi, product code: JS001) combined with axitinib for first-line treatment of medium- to high-risk patients with unresectable or metastatic renal cell cancer was approved. It is the first approved immunotherapy for kidney cancer in China.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

君实生物：特瑞普利单抗用于肾细胞癌一线治疗的新适应症上市申请获得批准

Junshi Biotech: Application for marketing of treprilizumab as a new indication for first-line treatment of renal cell carcinoma was approved

Risk Disclaimer

Statement